Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (COSM) has launched its e-commerce and subscription business in Australia, New Zealand and broader Oceania, with sales already underway. Customers can buy products through the company's online stores and choose recurring delivery at checkout.
The expansion follows a U.S. direct-to-consumer business that had 8,940 active subscriptions and 14,624 online checkout orders as of October 19, 2026. Cosmos Health intends to continue evaluating additional international markets for its direct-to-consumer subscription model as it builds a global recurring customer base.
Cosmos Health (COSM) reported preliminary nine-month revenue of approximately $54.3 million and reaffirmed its expectation for record full-year revenue. Revenue rose 19% year over year; the company expects 2026 revenue to surpass $90 million, implying fourth-quarter revenue of approximately $35.7 million or more.
Its U.S. business had 8,940 active subscriptions as of October 19. Cosmos expects approximately $15 million in fourth-quarter U.S. revenue at an approximately 70% gross margin, supported by a significantly expanded marketing budget. Cana's contract manufacturing pipeline exceeds 32.7 million units, with more than $20 million in implied revenue over the agreements' lives, subject to execution. Total liabilities fell 13.3% between December 2025 and June 2026. Cosmos targets a 35.5% gross margin by fiscal 2029, versus 12.1% in fiscal 2025, and has a non-binding acquisition letter of intent for a Greek pharmacy distribution network.
Cosmos Health (COSM) expects approximately $15 million in U.S. revenue for the fourth quarter of 2026 from its online direct-to-consumer business. The company forecasts approximately $10.5 million in gross profit at an approximately 70% gross margin, supported by an expanded marketing budget.
Expected revenue comprises approximately $8.2 million from new subscribers' first orders, $3.3 million from renewals of subscriptions started during the quarter and $3.5 million from one-time purchases. Active U.S. subscriptions reached 8,940 on October 19, up 42% from 6,287 on October 14; platform subscription and order figures are preliminary and unaudited. Cosmos Health expects daily U.S. sales to rise from $60,000 at the quarter's start to more than $200,000 by year-end, with active U.S. subscriptions exceeding 40,000 by year-end.
Cosmos Health (COSM) reached 6,287 active subscriptions in its U.S. online stores, substantially all added since mid-September 2026. The model launched in mid-July. Of 10,881 checkout orders tracked to date, 60.5% included a subscription; the current rate exceeds 75%. Another 4,297 orders were one-time purchases.
As of October 14, 2026, active subscriptions comprised 12,408 subscription lines and 14,793 product units, averaging approximately 2.4 units per subscription. Their aggregate monthly value at standard renewal pricing was $919,945, an operating metric rather than U.S. GAAP revenue. Subscription, order and unit figures are preliminary and unaudited; actual renewal revenue depends on customer renewal behavior.
The company intends to extend subscriptions to other portfolio brands and markets beyond the United States, following accelerated investment in its U.S. direct-to-consumer platform.
Cosmos Health (COSM) reported record United States direct-to-consumer sales of more than $92,000 in a single day on October 11, 2026. Sales over the trailing 30 days totaled $902,000, or approximately $30,000 per day. Average daily sales over the past 10 days exceeded $60,000, double the 30-day average.
The figures cover the company's own branded United States online stores, including 18 Series nutraceuticals, NOOR and skincare products, through individual purchases and subscriptions. Sustained for a full year, the 10-day rate would correspond to approximately $21.9 million in annualized sales; this is not a completed year's result. Cosmos Health projects annual revenue of over $23 million for its United States products within the next 12 to 18 months and is evaluating extending the direct-to-consumer model to additional portfolio brands and markets.
Cosmos Health (NASDAQ:COSM) reported preliminary nine-month revenue of approximately $54.3 million, up 19% from the same period in 2025.
Revenue for the nine months ended September 30, 2026 rose from $45.6 million and was 35% above 2024. Preliminary third-quarter revenue reached approximately $17.4 million, up 2% from $17.1 million in 2025 and 40% from $12.4 million in 2024. Each quarter of 2026 exceeded its previous corresponding-quarter revenue record. Cana Laboratories' production pipeline exceeded 32.7 million units; CosmoFarm recorded its highest distribution volumes, and proprietary brands expanded into new markets and channels.
The company reaffirmed expected 2026 revenue of over $90 million, approximately 38% above 2025, and expects its highest-ever fourth-quarter revenue. The preliminary figures are unaudited and remain subject to quarter-end closing procedures and review.
Cosmos Health (NASDAQ:COSM) outlined its healthcare brand portfolio, with products sold in more than 40 countries through multiple sales channels. The portfolio includes more than 15 proprietary brands and product lines and 10 branded generics across five categories, supported by manufacturing, distribution, telehealth and research services.
Cana Laboratories has a contract-manufacturing production pipeline exceeding 32.7 million units. Agreements average approximately four years and extend up to ten years; reported gross margins for this activity exceed 90%, excluding pharmaceutical distribution. Cosmos Health also has an advisory agreement with the European Investment Bank concerning a €50 million R&D program, with potential EIB financing of up to €25 million but no financing commitment. Its CCX0722 weight-management hydrogel remains in development, with further work and regulatory requirements pending.
Cosmos Health (COSM) reported record second-quarter 2026 revenue above $15 million at its CosmoFarm pharmacy distribution subsidiary.
That represents an annualized revenue run rate above $60 million, approximately 4.3 times CosmoFarm’s fiscal 2017 sales of approximately $14 million before its acquisition. The dollar-based growth figures reflect exchange-rate changes. Daily-served pharmacies rose from approximately 100 in 2017 to approximately 360 today. A signed 2026 letter of intent covers a network generating approximately €10 million (approximately $11.5 million) in annual gross revenue; a definitive agreement and closing conditions remain pending.
Cosmos Health expects expansion and automation to support $40 million or more in additional annual revenue capacity, potentially allowing CosmoFarm to operate above $100 million in annualized revenue if volume grows. The subsidiary is expected to contribute to Cosmos Health’s 2029 revenue target of $200.6 million.
Cosmos Health (COSM) said its Cana Laboratories contract-manufacturing pipeline surpassed 32.7 million units across existing agreements. The company estimates more than $20 million in implied revenue and $18 million in implied gross profit over the agreements’ lives, at gross margins above 90%. Agreements average approximately four years; some extend up to ten years.
The pipeline added 7.7 million units through two agreements in September and rose 31% since June. Cosmos estimates the current pipeline equates to approximately $5 million in annual revenue and $4.5 million in annual gross profit. These are estimates, not recognized revenue or GAAP profit; realized amounts depend on orders placed and their timing and mix. Cana targets over $10 million in recurring annual gross profit at full capacity. Cosmos also maintains 2029 guidance targets of $200.6 million in revenue and $71.2 million in gross profit.
Cosmos Health (COSM) announced that subsidiary Cana Laboratories has signed new five-year contract manufacturing agreements with Target Pharma covering approximately 5.2 million units, or about 1.04 million units annually.
The agreements for MUPIROCIN and TRETIN lift Cana’s cumulative orderbook to more than 32.7 million units, a 31% increase since June 2026, achieved through two agreements signed in under two weeks. September contracted volume additions total 7.7 million units, including the previously announced five-year ROSARTIA agreement with Viofar.
Cana’s contracted portfolio now spans 11 therapeutic categories, up from nine in June, with new coverage in cardiovascular and anti-infective. Agreements across the division extend up to ten years, which the company expects will support recurring production and associated cash flows.
Cana operates a 54,000-square-foot GMP-licensed, EMA-certified facility in Athens, upgraded with about $5.5 million of investment, and is targeted, at full capacity, to generate over $10 million in recurring annual profit.